5 women's health FDA headlines you missed in Q2 2026

We're officially at the halfway point of the year, and the past few months have delivered a steady stream of regulatory news for obstetricians-gynecologists (ob-gyns) to track. Below, the Contemporary OB/GYN team recaps some of the top FDA-related stories we covered last quarter, spanning cervical cancer screening, menopause therapeutics, and antibiotic treatment for urinary tract infections.